| Scorecard |
|---|
|
5 / 5 Stars
|
|
Lipper
---
|
|
Zacks Investment Research
3
(Hold)
|
|
Standard & Poor's
2 / 5 Stars
|
|
TheStreet.com
---
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 3.98 | 3.98 |
| Stocks | 82.99 | 82.99 |
| Bonds | 0.0 | 0.0 |
| Other | 4.02 | 4.02 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 9.01 | 9.01 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Biomarin Pharmaceutical, Inc. | BMRN | 29.43 | 7.04 |
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 4.99 |
| Vertex Pharmaceuticals | VRTX | 83.37 | 4.79 |
| Gilead Sciences Inc | GILD | 36.53 | 4.33 |
| Bristol-Myers Squibb Company | BMY | 24.03 | 4.15 |
| UnitedHealth Group Inc | UNH | 10.5 | 3.72 |
| Pfizer Inc | PFE | 16.19 | 3.71 |
| Biogen Idec Inc | BIIB | 46.43 | 3.02 |
| HCA Holdings Inc | HCA | 30.89 | 2.99 |
| Onyx Pharmaceuticals, Inc. | ONXX | 19.29 | 2.9 |
